Navellier & Associates Inc. Acquires 730 Shares of Cencora, Inc. (NYSE:COR)

Navellier & Associates Inc. boosted its holdings in Cencora, Inc. (NYSE:COR) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 20,007 shares of the company’s stock after purchasing an additional 730 shares during the period. Navellier & Associates Inc.’s holdings in Cencora were worth $4,495,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in COR. Hickory Asset Management Inc. purchased a new position in shares of Cencora in the fourth quarter valued at about $572,000. Sylvest Advisors LLC purchased a new position in shares of Cencora in the fourth quarter valued at about $1,105,000. Insight Wealth Strategies LLC increased its position in shares of Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after acquiring an additional 11,232 shares during the period. Cerity Partners LLC increased its position in shares of Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after acquiring an additional 3,610 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after acquiring an additional 2,928 shares during the period. 97.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on COR. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. UBS Group boosted their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Wells Fargo & Company boosted their price target on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Finally, Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Price Performance

Shares of NYSE COR opened at $241.47 on Friday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a 50 day simple moving average of $239.52 and a two-hundred day simple moving average of $237.46. The company has a market capitalization of $46.83 billion, a price-to-earnings ratio of 34.35, a P/E/G ratio of 1.32 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s dividend payout ratio is 31.29%.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.